Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Recursion Pharmaceuticals ( (RXRX) ) is now available.
On May 6, 2026, Recursion reported first-quarter 2026 results and business updates, highlighting multiple pipeline milestones and continued advancement of its AI-native Recursion OS platform. Early Phase 1/2 data for REC-1245, a potential first-in-class RBM39 degrader for solid tumors, showed a favorable safety and pharmacokinetic profile with no dose-limiting toxicities observed to date and ongoing dose escalation.
The company also reported strong Phase 2 efficacy signals for REC-4881 in familial adenomatous polyposis, with meaningful reductions in polyp burden and safety consistent with MEK1/2 inhibition, and it has begun FDA engagement on a potential registrational path. In addition, Recursion dosed the first patient in the Phase 1 ENLYGHT study of REC-4539, an AI-designed LSD1 inhibitor intended to mitigate platelet toxicity, reiterated disciplined capital plans with expected operational cash burn under $390 million in 2026 and runway into early 2028, and noted over $500 million already achieved in milestones and upfront payments from major discovery partnerships.
The most recent analyst rating on (RXRX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Recursion Pharmaceuticals stock, see the RXRX Stock Forecast page.
Spark’s Take on RXRX Stock
According to Spark, TipRanks’ AI Analyst, RXRX is a Neutral.
The score is anchored by mixed fundamentals: a strong cash position and accelerating revenue growth are offset by very large losses and heavy cash burn. Technicals are also weak (below key moving averages with negative MACD), while the latest earnings call was constructive on runway extension, cost reductions, and early clinical proof-of-concept, partially balancing the financial and momentum risks.
To see Spark’s full report on RXRX stock, click here.
More about Recursion Pharmaceuticals
Recursion Pharmaceuticals (Nasdaq: RXRX) is a clinical-stage TechBio company based in Salt Lake City that uses an AI-enabled, full-stack drug discovery and development platform, the Recursion Operating System, to decode biology and design novel therapeutics. The company focuses on oncology and genetically defined diseases, advancing both wholly owned and partnered programs with large pharma collaborators in immunology, oncology and neurology.
Average Trading Volume: 14,586,114
Technical Sentiment Signal: Sell
Current Market Cap: $1.86B
Find detailed analytics on RXRX stock on TipRanks’ Stock Analysis page.